Caitlin R. Rausch

Clinical experience with the <scp>BCL</scp>2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies

Courtney D. DiNardo, Caitlin R. Rausch, Christopher B. Benton et al. · American Journal of Hematology · 2017 · 437 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial

Courtney D. DiNardo, Abhishek Maiti, Caitlin R. Rausch et al. · The Lancet Haematology · 2020 · 331 citations · Full text

Medicine, Hematology, Oncology +16

Outcomes of <i>TP53</i>‐mutant acute myeloid leukemia with decitabine and venetoclax

Kunhwa Kim, Abhishek Maiti, Sanam Loghavi et al. · Cancer · 2021 · 158 citations · Full text

Medicine, Hematology, Pharmacology +16

Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia

Guillaume Richard‐Carpentier, Elias Jabbour, Nicholas J. Short et al. · Clinical Lymphoma Myeloma & Leukemia · 2019 · 127 citations

Medicine, Hematology, Oncology +14

Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Tapan M. Kadia, Patrick K. Reville, Xuemei Wang et al. · Journal of Clinical Oncology · 2022 · 114 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16